Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Total Current Liabilities (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of Total Current Liabilities data on record, last reported at $11.5 million in Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 12.43% year-over-year to $11.5 million; the TTM value through Dec 2025 reached $11.5 million, up 12.43%, while the annual FY2025 figure was $11.5 million, 12.43% up from the prior year.
  • Total Current Liabilities reached $11.5 million in Q4 2025 per TLSI's latest filing, up from $10.9 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $32.4 million in Q4 2022 and bottomed at $1.7 million in Q2 2022.
  • Average Total Current Liabilities over 4 years is $10.2 million, with a median of $10.1 million recorded in 2024.
  • The widest YoY moves for Total Current Liabilities: up 386.22% in 2023, down 54.61% in 2023.
  • A 4-year view of Total Current Liabilities shows it stood at $32.4 million in 2022, then tumbled by 54.61% to $14.7 million in 2023, then tumbled by 30.36% to $10.2 million in 2024, then rose by 12.43% to $11.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $11.5 million in Q4 2025, $10.9 million in Q3 2025, and $9.3 million in Q2 2025.